In a recent study, published in PNAS, researchers developed an ingenious point-of-care diagnostic method using synthetic peptide biomarkers and immunoassays. The method was capable of detecting and quantifying colorectal cancer and thrombosis biomarkers directly from unpurified urine.


Learn more >>


With additional development, the test is proposed to be applicable for detection of a host of noncommunicable diseases, without the requirement for expensive equipment or medically trained personnel. The cost of manufacturing a simple lateral flow assay device was estimated to be less than $2.60 per test.